Celldex Therapeutics (CLDX) Enterprise Value (2010 - 2026)

Celldex Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$451.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 32.95% year-over-year to -$451.5 million in Q1 2026; TTM through Mar 2026 was -$451.5 million, a 32.95% increase from a year earlier, with the FY2025 full-year figure at -$518.6 million, up 28.5% from the prior year.
• Enterprise Value grew to -$451.5 million in Q1 2026 per CLDX's latest filing, from -$518.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$235.3 million in Q3 2023 and bottomed at -$823.8 million in Q1 2024.
• The 5-year median for Enterprise Value is -$451.5 million (2026), against an average of -$501.2 million.
• Across the five-year window, Enterprise Value sank 221.23% in 2024 and jumped 32.95% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$305.0 million in 2022, then sank by 38.91% to -$423.6 million in 2023, then plunged by 71.22% to -$725.3 million in 2024, then gained by 28.5% to -$518.6 million in 2025, then advanced by 12.94% to -$451.5 million in 2026.
• Per Business Quant, the three latest CLDX Enterprise Value figures stand at -$451.5 million (Q1 2026), -$518.6 million (Q4 2025), and -$583.2 million (Q3 2025).